Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN, COV-BOOST study group.

Open source

DOI: 10.1016/s1473-3099(22)00271-7
Published: 2022-05-09
Container: Lancet Infect Dis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-22-00271-7,
  title = {Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.},
  author = {Munro APS and  Feng S and  Janani L and  Cornelius V and  Aley PK and  Babbage G and  Baxter D and  Bula M and  Cathie K and  Chatterjee K and  Dodd K and  Enever Y and  Qureshi E and  Goodman AL and  Green CA and  Harndahl L and  Haughney J and  Hicks A and  van der Klaauw AA and  Kanji N and  Libri V and  Llewelyn MJ and  McGregor AC and  Maallah M and  Minassian AM and  Moore P and  Mughal M and  Mujadidi YF and  Holliday K and  Osanlou O and  Osanlou R and  Owens DR and  Pacurar M and  Palfreeman A and  Pan D and  Rampling T and  Regan K and  Saich S and  Bawa T and  Saralaya D and  Sharma S and  Sheridan R and  Thomson EC and  Todd S and  Twelves C and  Read RC and  Charlton S and  Hallis B and  Ramsay M and  Andrews N and  Lambe T and  Nguyen-Van-Tam JS and  Snape MD and  Liu X and  Faust SN and  COV-BOOST study group.},
  year = {2022},
  journal = {Lancet Infect Dis},
  doi = {10.1016/s1473-3099(22)00271-7},
  url = {https://doi.org/10.1016/s1473-3099(22)00271-7}
}

RIS

TY  - JOUR
TI  - Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
AU  - Munro APS
AU  -  Feng S
AU  -  Janani L
AU  -  Cornelius V
AU  -  Aley PK
AU  -  Babbage G
AU  -  Baxter D
AU  -  Bula M
AU  -  Cathie K
AU  -  Chatterjee K
AU  -  Dodd K
AU  -  Enever Y
AU  -  Qureshi E
AU  -  Goodman AL
AU  -  Green CA
AU  -  Harndahl L
AU  -  Haughney J
AU  -  Hicks A
AU  -  van der Klaauw AA
AU  -  Kanji N
AU  -  Libri V
AU  -  Llewelyn MJ
AU  -  McGregor AC
AU  -  Maallah M
AU  -  Minassian AM
AU  -  Moore P
AU  -  Mughal M
AU  -  Mujadidi YF
AU  -  Holliday K
AU  -  Osanlou O
AU  -  Osanlou R
AU  -  Owens DR
AU  -  Pacurar M
AU  -  Palfreeman A
AU  -  Pan D
AU  -  Rampling T
AU  -  Regan K
AU  -  Saich S
AU  -  Bawa T
AU  -  Saralaya D
AU  -  Sharma S
AU  -  Sheridan R
AU  -  Thomson EC
AU  -  Todd S
AU  -  Twelves C
AU  -  Read RC
AU  -  Charlton S
AU  -  Hallis B
AU  -  Ramsay M
AU  -  Andrews N
AU  -  Lambe T
AU  -  Nguyen-Van-Tam JS
AU  -  Snape MD
AU  -  Liu X
AU  -  Faust SN
AU  -  COV-BOOST study group.
PY  - 2022
JO  - Lancet Infect Dis
DO  - 10.1016/s1473-3099(22)00271-7
UR  - https://doi.org/10.1016/s1473-3099(22)00271-7
ER  -

APA

APS, M., S, F., L, J., V, C., PK, A., G, B., D, B., M, B., K, C., K, C., K, D., Y, E., E, Q., AL, G., CA, G., L, H., J, H., A, H., AA, V. D. K., N, K., V, L., MJ, L., AC, M., M, M., AM, M., P, M., M, M., YF, M., K, H., O, O., R, O., DR, O., M, P., A, P., D, P., T, R., K, R., S, S., T, B., D, S., S, S., R, S., EC, T., S, T., C, T., RC, R., S, C., B, H., M, R., N, A., T, L., JS, N., MD, S., X, L., SN, F., & group., C. S. (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.. Lancet Infect Dis. https://doi.org/10.1016/s1473-3099(22)00271-7

Source records

europe-pmc · retrieved 2026-09-27T12:27:22.637Z